Bank of New York Mellon Corp Boosts Holdings in Elevance Health, Inc. $ELV

Bank of New York Mellon Corp boosted its holdings in shares of Elevance Health, Inc. (NYSE:ELV) by 3.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,343,639 shares of the company’s stock after buying an additional 42,821 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.60% of Elevance Health worth $434,157,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in ELV. Vanguard Group Inc. raised its holdings in Elevance Health by 3.2% in the 2nd quarter. Vanguard Group Inc. now owns 22,856,898 shares of the company’s stock worth $8,890,419,000 after purchasing an additional 704,790 shares during the period. Sanders Capital LLC increased its position in Elevance Health by 24.7% in the second quarter. Sanders Capital LLC now owns 5,825,208 shares of the company’s stock worth $2,265,773,000 after buying an additional 1,152,440 shares in the last quarter. Artisan Partners Limited Partnership raised its stake in shares of Elevance Health by 9.7% in the second quarter. Artisan Partners Limited Partnership now owns 3,675,179 shares of the company’s stock worth $1,429,498,000 after buying an additional 324,399 shares during the period. Norges Bank purchased a new position in shares of Elevance Health during the 2nd quarter valued at about $1,148,379,000. Finally, Massachusetts Financial Services Co. MA grew its stake in shares of Elevance Health by 4.8% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,440,630 shares of the company’s stock valued at $788,616,000 after acquiring an additional 112,020 shares during the period. 89.24% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ELV has been the topic of a number of recent analyst reports. Weiss Ratings upgraded shares of Elevance Health from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, January 12th. The Goldman Sachs Group began coverage on shares of Elevance Health in a research report on Tuesday, October 14th. They set a “neutral” rating and a $343.00 price objective on the stock. Wolfe Research set a $425.00 target price on shares of Elevance Health and gave the stock an “outperform” rating in a report on Thursday, January 8th. TD Cowen reiterated a “buy” rating on shares of Elevance Health in a research note on Wednesday, November 26th. Finally, Robert W. Baird boosted their price objective on Elevance Health from $297.00 to $340.00 and gave the company a “neutral” rating in a research report on Thursday, December 11th. Twelve analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $399.63.

Elevance Health News Summary

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q4 EPS beat consensus ($3.33 vs. $3.10) and management cited rising premiums plus a surge in Carelon revenues — a key reason investors see continued earnings resilience. Elevance Health Q4 Earnings Beat
• Positive Sentiment: Board raised the quarterly dividend to $1.72 (annualized yield ~2.0%), a modest increase from $1.71 — supportive for income-focused shareholders and signals confidence in cash flow.
• Neutral Sentiment: Revenue grew ~9.6% YoY to $49.31B but came in slightly below consensus; net margin and ROE remain modest, so growth is present but profit dynamics are mixed. Press Release / Slide Deck
• Negative Sentiment: FY?2026 EPS guidance was lowered to about 25.50, below the Street (~26.89); management warned medical costs will remain elevated, which is a direct near?term headwind to margins and valuation. Elevance forecasts 2026 profit below estimates
• Negative Sentiment: Market commentary highlights Medicare Advantage and reimbursement/membership pressures as reasons for selloff and heightened volatility in ELV shares following the earnings release. Barron’s: Earnings adding to Medicare pain

Elevance Health Stock Up 5.9%

Shares of ELV stock opened at $342.01 on Thursday. The company’s fifty day simple moving average is $350.56 and its two-hundred day simple moving average is $328.87. Elevance Health, Inc. has a 52 week low of $273.71 and a 52 week high of $458.75. The stock has a market cap of $76.01 billion, a P/E ratio of 13.98, a PEG ratio of 1.66 and a beta of 0.51. The company has a quick ratio of 1.56, a current ratio of 1.56 and a debt-to-equity ratio of 0.71.

Elevance Health (NYSE:ELV) last issued its earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.10 by $0.23. Elevance Health had a return on equity of 16.17% and a net margin of 2.84%.The firm had revenue of $49.31 billion for the quarter, compared to analysts’ expectations of $49.52 billion. During the same period in the previous year, the firm posted $3.84 earnings per share. The business’s revenue was up 9.6% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Analysts predict that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be issued a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.0%. This is a boost from Elevance Health’s previous quarterly dividend of $1.71. The ex-dividend date of this dividend is Tuesday, March 10th. Elevance Health’s payout ratio is 27.96%.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.